🔴 Lantern Pharma is trading 6.4% down today with no clear company-specific catalyst identified

Lantern Pharma is trading at $2.19, down -6.41%, with no clear company-specific announcement or catalyst identified for August 24, 2026.

• Investor sentiment may still reflect Lantern Pharma’s August 14 second-quarter report, which showed a $7.1 million net loss and a wider-than-expected $0.57 per-share loss.
• Broader conditions were mixed to lower, with the Nasdaq Composite down 0.63%, but evidence does not establish it as the direct cause. The decline remains unexplained.